A NONLINEAR DOSIMETRIC MODEL FOR HEMOGLOBIN ADDUCT FORMATION BY THE NEUROTOXIC AGENT ACRYLAMIDE AND ITS GENOTOXIC METABOLITE GLYCIDAMIDE

被引:22
作者
CALLEMAN, CJ [1 ]
BERGMARK, E [1 ]
STERN, LG [1 ]
COSTA, LG [1 ]
机构
[1] UNIV WASHINGTON HOSP,DEPT APPL MATH,SEATTLE,WA 98195
关键词
D O I
10.2307/3431486
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Hemoglobin (Hb) adducts, formed by the neurotoxic agent acrylamide (AA) and its genotoxic metabolite glycidamide (GA), were measured in the rat by means of a method for simultaneous determination of the adducts formed to cysteine. A novel, nonlinear dosimetric model was developed to describe Hb adduct formation. This model incorporates the saturable kinetics of the metabolic conversion in vivo of AA to GA. The pharmacokinetic parameters V(max) and K(m) and the first-order rates of elimination, k1 and k2, for AA and GA from all processes except conversion of AA to GA, were estimated directly from Hb adduct data to 19 M hr-1, 66 mM, 0.21 hr-1, and 0.48 hr-1, respectively. At low concentrations, approximately 60% of AA was metabolized to GA. The nonlinear dosimetric model for adduct formation has potential general applicability in high-to-low-dose extrapolation of genotoxic effects.
引用
收藏
页码:221 / 223
页数:3
相关论文
共 10 条
[1]   MONITORING EXPOSURE TO ACRYLAMIDE BY THE DETERMINATION OF S-(2-CARBOXYETHYL)CYSTEINE IN HYDROLYZED HEMOGLOBIN BY GAS-CHROMATOGRAPHY MASS-SPECTROMETRY [J].
BAILEY, E ;
FARMER, PB ;
BIRD, I ;
LAMB, JH ;
PEAL, JA .
ANALYTICAL BIOCHEMISTRY, 1986, 157 (02) :241-248
[2]  
BEREGMARK E, 1991, TOXICOL APPL PHARM, V111, P352
[3]   ACRYLAMIDE IS METABOLIZED TO GLYCIDAMIDE IN THE RAT - EVIDENCE FROM HEMOGLOBIN ADDUCT FORMATION [J].
CALLEMAN, CJ ;
BERGMARK, E ;
COSTA, LG .
CHEMICAL RESEARCH IN TOXICOLOGY, 1990, 3 (05) :406-412
[4]  
CALLEMAN CJ, 1992, CANCER EPIDEM BIOMAR, V1, P361
[5]  
COSTA LG, 1991, 3RD P INT NEUR ASS M
[6]  
DEARFIELD KL, 1988, MUTAT RES, V195, P15
[7]   MUTAGENICITY OF ACRYLAMIDE AND ITS ANALOGS IN SALMONELLA-TYPHIMURIUM [J].
HASHIMOTO, K ;
TANII, H .
MUTATION RESEARCH, 1985, 158 (03) :129-133
[8]   PHARMACOKINETICS OF ACRYLAMIDE IN FISHER-334 RATS [J].
MILLER, MJ ;
CARTER, DE ;
SIPES, IG .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1982, 63 (01) :36-44
[9]   EVALUATION OF GENETIC RISKS OF ALKYLATING-AGENTS .2. HEMOGLOBIN AS A DOSE MONITOR [J].
OSTERMANGOLKAR, S ;
EHRENBERG, L ;
SEGERBACK, D ;
HALLSTROM, I .
MUTATION RESEARCH, 1976, 34 (01) :1-10
[10]  
1988, PRELIMINARY ASSESSME